Opioid Modulation of Oxytocin Release
dc.contributor.author | Morris, Mark S. | en_US |
dc.contributor.author | Domino, Edward F. | en_US |
dc.contributor.author | Domino, Steven E. | en_US |
dc.date.accessioned | 2013-04-08T20:49:38Z | |
dc.date.available | 2013-04-08T20:49:38Z | |
dc.date.issued | 2010-10 | en_US |
dc.identifier.citation | Morris, Mark S.; Domino, Edward F.; Domino, Steven E. (2010). "Opioid Modulation of Oxytocin Release." The Journal of Clinical Pharmacology 50(10). <http://hdl.handle.net/2027.42/97182> | en_US |
dc.identifier.issn | 0091-2700 | en_US |
dc.identifier.issn | 1552-4604 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/97182 | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Parturition | en_US |
dc.subject.other | Vasopressin | en_US |
dc.subject.other | Mu‐Kappa‐Delta Opioid Receptors | en_US |
dc.subject.other | Morphine | en_US |
dc.subject.other | Endogenous Opioids | en_US |
dc.subject.other | Meperidine | en_US |
dc.subject.other | Oxytocin | en_US |
dc.title | Opioid Modulation of Oxytocin Release | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Obstetrics and Gynecology, University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | Departments of Pharmacology, University of Michigan, Ann Arbor | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/97182/1/0091270010361256.pdf | |
dc.identifier.doi | 10.1177/0091270010361256 | en_US |
dc.identifier.source | The Journal of Clinical Pharmacology | en_US |
dc.identifier.citedreference | Carvalho B. Respiratory depression after neuraxial opioids in the obstetric setting. Anesth Analg. 2008; 107: 956 – 961. | en_US |
dc.identifier.citedreference | Van de Heijning BJM, Van den Koekkoek‐Herik I, Maigret C, et al. Pharmacological assessment of the site of action of opioids on the release of vasopressin and oxytocin in the rat. Eur J Pharmacol. 1991; 197: 175 – 180. | en_US |
dc.identifier.citedreference | Van de Heijning BJM, Van den Koekkoek‐Herik I, Van Wimersma Greidanus TB. The opioid receptor subtypes mu and kappa, but not delta, are involved in the control of the vasopressin and oxytocin release in the rat. Eur J Pharmacol. 1991; 209: 199 – 206. | en_US |
dc.identifier.citedreference | Dayanithi G, Stuenkel E, Nordmann JJ. Intracellular calcium and hormone release from nerve endings of the neurohypophysics in the presence of opioid agonists and antagonists. Exp Brain Res. 1992; 90: 539 – 545. | en_US |
dc.identifier.citedreference | Brown CH, Russell JA, Leng G. Opioid modulation of magnocellular neurosecretory cell activity. Neurosci Res. 2000; 36: 97 – 120. | en_US |
dc.identifier.citedreference | Bicknell RJ, Leng G. Endogenous opiates regulate oxytocin but not vasopressin secretion from the neurohypophysis. Nature. 1982; 298: 161 – 162. | en_US |
dc.identifier.citedreference | Bondy CA, Gainer H, Russell JT. Dynorphin A inhibits and naloxone increases the electrically stimulated release of oxytocin but not vasopressin from the terminals of the neural lobe. Endocrinology. 1988; 122: 1321 – 1327. | en_US |
dc.identifier.citedreference | Shuster SJ, Riedl M, Li X, et al. The kappa opioid receptor and dynorphin co‐localize in vasopressin magnocellular neurosecretory neurons in guinea‐pig hypothalamus. Neuroscience. 2000; 96: 373 – 383. | en_US |
dc.identifier.citedreference | Grell S, Fjalland B, Christensen JD. Biphasic effect of a kappa‐opioid receptor agonist on plasma oxytocin levels in rats. Eur J Pharmacol. 1989; 166: 41 – 48. | en_US |
dc.identifier.citedreference | Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008; 11: S133 – S153. | en_US |
dc.identifier.citedreference | O'Connor AB, Lang VJ, Quill TE. Eliminating analgesic meperidine use with a supported formulary restriction. Am J Med. 2005; 118: 885 – 889. | en_US |
dc.identifier.citedreference | Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: Evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy. 2004; 24: 776 – 783. | en_US |
dc.identifier.citedreference | Vermeulen LC, Bollinger KA, Antonopoulos J, et al. Multifaceted approach to medication use policy development: the restriction of meperidine. Pharm Pract Manage Q. 1997; 16: 66 – 75. | en_US |
dc.identifier.citedreference | Marcus MA, Gogarten G, Aken HV. Opioids in obstetrics: which route of administration with which opioid do we choose to establish effective analgesia? Eur J Anaesthesiol. 1998; 15: 140 – 146. | en_US |
dc.identifier.citedreference | Friedman EA. Primigravid labor: a graphicostatistical analysis. Obstet Gynecol. 1955; 6: 567 – 589. | en_US |
dc.identifier.citedreference | Greulich B, Tarrant B. The latent phase of labor: diagnosis and management. J Midwife Womens Hlth. 2007; 53: 190 – 198. | en_US |
dc.identifier.citedreference | Russell JA, Leng G, Bicknell RJ. Opioid tolerance and dependence in the magnocellular oxytocin system: a physiological mechanism? Exper Physiol. 1995; 80: 307 – 340. | en_US |
dc.identifier.citedreference | Douglas AJ, Dye S, Leng G, et al. Endogenous opioid regulation of oxytocin secretion through pregnancy in the rat. J Neuroendocrinol. 1993; 5: 307 – 314. | en_US |
dc.identifier.citedreference | Leng G, Dye S, Bicknell RJ. Kappa‐opioid restraint of oxytocin secretion: plasticity through pregnancy. Neuroendocrinology. 1997; 66: 378 – 383. | en_US |
dc.identifier.citedreference | Kutlu S, Yilmaz B, Canpolat S, et al. Mu opioid modulation of oxytocin secretion in late pregnant and parturient rats: involvement of noradrenergic neurotransmission. Neuroendocrinology. 2004; 79: 197 – 203. | en_US |
dc.identifier.citedreference | Ji Y, Mei J, Lu S. Opposing effects of intracerebroventricularly injected norepinephrine on oxytocin and vasopressin neurons in the paraventricular nucleus of the rat. Neurosci Lett. 1998; 244: 13 – 16. | en_US |
dc.identifier.citedreference | Dondi D, Maggi R, Panerai AE, et al. Hypothalamic opiatergic tone during pregnancy, parturition and lactation in the rat. Neuroendocrinology. 1991; 53: 460 – 466. | en_US |
dc.identifier.citedreference | Boersma CJ, Van Leeuwen FW. Neuron‐glia interactions in the release of oxytocin and vasopressin from the rat neural lobe: the role of opioids, other neuropeptides and their receptors. Neuroscience. 1994; 62: 1003 – 1020. | en_US |
dc.identifier.citedreference | Douglas AJ, Russell JA. Endogenous opioid regulation of oxytocin and ACTH secretion during pregnancy and parturition. Prog Brain Res. 2001; 133: 67 – 82. | en_US |
dc.identifier.citedreference | Neumann I, Russell JA, Landgraf R. Endogenous opioids regulate intracerebral oxytocin release during parturition in a region‐specific manner. Prog Brain Res. 1992; 91: 55 – 58. | en_US |
dc.identifier.citedreference | Nelson EE, Panksepp J. Brain substrates of infant‐mother attachment: contribution of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev. 1998; 22: 437 – 452. | en_US |
dc.identifier.citedreference | Russell JA, Leng G, Douglas AJ. The magnocellular oxytocin system, the fount of maternity: adaptations in pregnancy. Front Neuroendocrinol. 2003; 24: 27 – 61. | en_US |
dc.identifier.citedreference | Center for Disease Control and Prevention. Births: Final Data for 2006. January 7, 2009. http:www.cdc.gov. Accessed June 22, 2009. | en_US |
dc.identifier.citedreference | Ullman R, Dowswell T, Mori R. Parenteral opioids for maternal pain relief in labour. Cochrane Database Syst Rev. 2008;(4):CD007396. | en_US |
dc.identifier.citedreference | DeVoe SJ, DeVoe K Jr., Rigsby WC, McDaniels BA. Effect of meperidine on uterine contractility. Am J Obstet Gyn. 1969; 105: 1004 – 1007. | en_US |
dc.identifier.citedreference | Frost JJ, Wagner HN Jr., Dannals RF, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomograp. 1985; 9: 231 – 236. | en_US |
dc.identifier.citedreference | Wagner HN Jr. Radiolabeled drugs as probes of central nervous system neurons. Clin Chem. 1985; 31: 1521 – 1524. | en_US |
dc.identifier.citedreference | Simantov R, Snyder SH. Opiate receptor binding in the pituitary gland. Brain Res. 1977; 124: 178 – 184. | en_US |
dc.identifier.citedreference | Dalayeun JF, Nores JM, Bergal S. Physiology of beta‐endorphin: a close‐up view and a review of the literature. Biomed Pharmacother. 1993; 47: 311 – 320. | en_US |
dc.identifier.citedreference | Jordan D, Tafani JAM, Ries C, et al. Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocrinol. 1996; 8: 883 – 887. | en_US |
dc.identifier.citedreference | Weerts EM, Kim YK, Wand GS, et al. Differences in δ‐ and μ‐opioid receptor blockade measured by positron emission tomography in naltrexone‐treated recently abstinent alcohol‐dependent subjects. Neuropsychopharmacology. 2008; 33: 653 – 665. | en_US |
dc.identifier.citedreference | Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Parker KL, Murri N, et al, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw‐Hill; 2006. | en_US |
dc.identifier.citedreference | Lutz‐Bucher B, Koch B. Evidence for a direct inhibitory effect of morphine on the secretion of posterior pituitary hormones. Eur J Pharmacol. 1980; 66: 375 – 378. | en_US |
dc.identifier.citedreference | Clarke G, Patrick G. Differential inhibitory action by morphine on the release of oxytocin and vasopressin from the isolated neural lobe. Neurosci Lett. 1983; 39: 175 – 180. | en_US |
dc.identifier.citedreference | Bicknell RJ, Leng G, Russell JA, Dyer RG, Mansfield S, Zhao BG. Hypothalamic opioids mechanisms controlling oxytocin neurons during parturition. Brain Res. 1988; 20: 743 – 749. | en_US |
dc.identifier.citedreference | Zhao BG, Chapman C, Bicknell RJ. Functional κ‐opioid receptors on oxytocin and vasopressin nerve terminals isolated from the rat neurohypophysis. Brain Res. 1988; 462: 62 – 66. | en_US |
dc.identifier.citedreference | Pumford K, Leng G, Russell JA. Morphine actions on supraoptic oxytocin neurons in anaesthetized rats: tolerance after i.c.v. morphine infusion. J Physiol. 1991; 440: 437 – 454. | en_US |
dc.identifier.citedreference | Ortiz‐Miranda S, Dayanithi G, Coccia V, et al. μ‐Opioid receptor modulates peptide release from rat neurohypophysial terminals by inhibiting Ca 2+ influx. J Neuroendocrinol. 2003; 15: 888 – 894. | en_US |
dc.identifier.citedreference | Ortiz‐Miranda S, Dayanithi G, Custer E, Treistman SN, Lernos JR. μ‐Opioid receptor preferentially inhibits oxytocin release from neurohypophysial terminals by blocking R‐type Ca 2+ channels. J Neuroendocrinol. 2005; 17: 583 – 590. | en_US |
dc.identifier.citedreference | Zhao BG, Chapman C, Brown D, et al. Opioid‐noradrenergic interactions in the neurohypophysis: II. Does noradrenaline mediate the actions of endogenous opioids on oxytocin and vasopressin release? Neuroendocrinology. 1988; 48: 25 – 31. | en_US |
dc.identifier.citedreference | Bicknell RJ, Zhao BG, Chapman C, et al. Opioid inhibition of secretion from oxytocin and vasopressin nerve terminals following selective depletion of neurohypophysical catecholamines. Neurosci Lett. 1988; 93: 281 – 286. | en_US |
dc.identifier.citedreference | Kato M, Chapman C, Bicknell RJ. Activation of κ‐opioid receptors inhibits depolarization‐evoked exocytosis but not the rise in intracellular Ca 2+ in secretory nerve terminals of the neurohypophysis. Brain Res. 1992; 574: 138 – 146. | en_US |
dc.identifier.citedreference | Russell JA, Coombes JE, Leng G, et al. Morphine tolerance and inhibition of oxytocin secretion by kappa‐opioids acting on the rat neurohypophysis. J Physiol. 1993; 469: 365 – 386. | en_US |
dc.identifier.citedreference | Zhao BG, Chapman C, Bicknell RJ. Opioid‐noradrenergic interactions in the neurohypophysis: I. Differential opioid receptor regulation of oxytocin, vasopressin, and noradrenaline release. Neuroendocrinology. 1988; 48: 16 – 24. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.